M Lukács1,2, K Warfvinge3,4, J Tajti5, F Fülöp6, J Toldi7,8, L Vécsei5,8, L Edvinsson3,4. 1. Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Lund, Sweden. lukacs_melici@yahoo.com. 2. Department of Neurology, University of Szeged, 6725 Semmelweis street nr. 6, Szeged, Hungary. lukacs_melici@yahoo.com. 3. Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Lund, Sweden. 4. Department of Clinical Experimental Research, Copenhagen University, Glostrup Hospital, Copenhagen, Denmark. 5. Department of Neurology, University of Szeged, 6725 Semmelweis street nr. 6, Szeged, Hungary. 6. Institute of Pharmaceutical Chemistry and MTA-SZTE Research Group for Stereochemistry, University of Szeged, Szeged, Hungary. 7. Department of Physiology, Anatomy and Neuroscience, University of Szeged, Szeged, Hungary. 8. MTA SZTE Neuroscience Research Group, Szeged, Hungary.
Abstract
BACKGROUND: Migraine is a debilitating neurological disorder where trigeminovascular activation plays a key role. We have previously reported that local application of Complete Freund's Adjuvant (CFA) onto the dura mater caused activation in rat trigeminal ganglion (TG) which was abolished by a systemic administration of kynurenic acid (KYNA) derivate (SZR72). Here, we hypothesize that this activation may extend to the trigeminal complex in the brainstem and is attenuated by treatment with SZR72. METHODS: Activation in the trigeminal nucleus caudalis (TNC) and the trigeminal tract (Sp5) was achieved by application of CFA onto the dural parietal surface. SZR72 was given intraperitoneally (i.p.), one dose prior CFA deposition and repeatedly daily for 7 days. Immunohistochemical studies were performed for mapping glutamate, c-fos, PACAP, substance P, IL-6, IL-1β and TNFα in the TNC/Sp5 and other regions of the brainstem and at the C1-C2 regions of the spinal cord. RESULTS: We found that CFA increased c-fos and glutamate immunoreactivity in TNC and C1-C2 neurons. This effect was mitigated by SZR72. PACAP positive fibers were detected in the fasciculus cuneatus and gracilis. Substance P, TNFα, IL-6 and IL-1β immunopositivity were detected in fibers of Sp5 and neither of these molecules showed any change in immunoreactivity following CFA administration. CONCLUSION: This is the first study demonstrating that dural application of CFA increases the expression of c-fos and glutamate in TNC neurons. Treatment with the KYNA analogue prevented this expression.
BACKGROUND:Migraine is a debilitating neurological disorder where trigeminovascular activation plays a key role. We have previously reported that local application of Complete Freund's Adjuvant (CFA) onto the dura mater caused activation in rat trigeminal ganglion (TG) which was abolished by a systemic administration of kynurenic acid (KYNA) derivate (SZR72). Here, we hypothesize that this activation may extend to the trigeminal complex in the brainstem and is attenuated by treatment with SZR72. METHODS: Activation in the trigeminal nucleus caudalis (TNC) and the trigeminal tract (Sp5) was achieved by application of CFA onto the dural parietal surface. SZR72 was given intraperitoneally (i.p.), one dose prior CFA deposition and repeatedly daily for 7 days. Immunohistochemical studies were performed for mapping glutamate, c-fos, PACAP, substance P, IL-6, IL-1β and TNFα in the TNC/Sp5 and other regions of the brainstem and at the C1-C2 regions of the spinal cord. RESULTS: We found that CFA increased c-fos and glutamate immunoreactivity in TNC and C1-C2 neurons. This effect was mitigated by SZR72. PACAP positive fibers were detected in the fasciculus cuneatus and gracilis. Substance P, TNFα, IL-6 and IL-1β immunopositivity were detected in fibers of Sp5 and neither of these molecules showed any change in immunoreactivity following CFA administration. CONCLUSION: This is the first study demonstrating that dural application of CFA increases the expression of c-fos and glutamate in TNC neurons. Treatment with the KYNA analogue prevented this expression.
Authors: Ling-Hsuan Kung; Kerui Gong; Mary Adedoyin; Johnson Ng; Aditi Bhargava; Peter T Ohara; Luc Jasmin Journal: PLoS One Date: 2013-07-02 Impact factor: 3.240
Authors: Edina K Cseh; Gábor Veres; Tamás Körtési; Helga Polyák; Nikolett Nánási; János Tajti; Árpád Párdutz; Péter Klivényi; László Vécsei; Dénes Zádori Journal: J Headache Pain Date: 2020-04-21 Impact factor: 7.277
Authors: László Juhász; Attila Rutai; Roland Fejes; Szabolcs P Tallósy; Marietta Z Poles; Andrea Szabó; István Szatmári; Ferenc Fülöp; László Vécsei; Mihály Boros; József Kaszaki Journal: Front Med (Lausanne) Date: 2020-11-27
Authors: Kinga Molnár; Bálint Lőrinczi; Csilla Fazakas; István Szatmári; Ferenc Fülöp; Noémi Kmetykó; Róbert Berkecz; István Ilisz; István A Krizbai; Imola Wilhelm; László Vécsei Journal: Pharmaceutics Date: 2021-01-05 Impact factor: 6.321
Authors: Zsolt Balla; Eszter Sára Kormányos; Balázs Kui; Emese Réka Bálint; Gabriella Fűr; Erik Márk Orján; Béla Iványi; László Vécsei; Ferenc Fülöp; Gabriella Varga; András Harazin; Vilmos Tubak; Mária A Deli; Csaba Papp; Attila Gácser; Tamara Madácsy; Viktória Venglovecz; József Maléth; Péter Hegyi; Lóránd Kiss; Zoltán Rakonczay Journal: Front Immunol Date: 2021-10-21 Impact factor: 7.561
Authors: Viktória Kovács; Gábor Remzső; Tímea Körmöczi; Róbert Berkecz; Valéria Tóth-Szűki; Andrea Pénzes; László Vécsei; Ferenc Domoki Journal: Int J Mol Sci Date: 2021-05-01 Impact factor: 5.923